Combined Bcl-2 and NF-κB inhibition inhibits CTCL tumor growth and increases survival in an orthotopic SeAx xenograft model. NSG mice were xenografted with SeAx cells intradermally. Treatment of transplanted mice was with either vehicle, 1 treatment of ABT-199, once daily treatment with DMF for 28 days or the combination of a single application of ABT-199 and the 28 days treatment with a daily application of DMF (n = 8, each). (A) Median tumor volume upon treatment with vehicle, ABT-199, DMF and the combination. *P < .05 of the combination-treatment vs vehicle-treated control. (B) Percent reduction in tumor growth at day 18 of mice treated with PBS, ABT-199, DMF or combination. *P < .05 from vehicle-treated control. (C) Survival curves of xenografted mice in the different treatment groups, as indicated. Decrease in survival is reflecting the reach of the end points defined in "Materials and methods." (D) Percent survival rate of orthotopically xenografted mice treated with vehicle or DMF at day 30, 1 day after the end of the treatment phase. (E) Mean survival time of the SeAx tumor bearers in the different treatment groups, as indicated. *P < .05 vs vehicle-treated control.